IVERIC bio, Inc. (ISEE): Price and Financial Metrics

IVERIC bio, Inc. (ISEE): $39.95

0.15 (+0.38%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add ISEE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#353 of 381

in industry

ISEE Price/Volume Stats

Current price $39.95 52-week high $39.99
Prev. close $39.80 52-week low $9.39
Day low $39.85 Volume 10,999,100
Day high $39.99 Avg. volume 3,616,141
50-day MA $38.02 Dividend yield N/A
200-day MA $26.09 Market Cap 5.50B

ISEE Stock Price Chart Interactive Chart >


IVERIC bio, Inc. (ISEE) Company Bio


IVERIC bio, Inc. (formerly Ophthotech Corporation) is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). The company was founded in 2007 and is based in New York, New York.


ISEE Latest News Stream


Event/Time News Detail
Loading, please wait...

ISEE Latest Social Stream


Loading social stream, please wait...

View Full ISEE Social Stream

Latest ISEE News From Around the Web

Below are the latest news stories about IVERIC BIO INC that investors may wish to consider to help them evaluate ISEE as an investment opportunity.

Astellas Completes Acquisition of Iveric Bio

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio") with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary.

Yahoo | July 11, 2023

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARSIPPANY, N.J., July 05, 2023--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees.

Yahoo | July 5, 2023

Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why

Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.

Yahoo | May 30, 2023

Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma

Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying.

Yahoo | May 1, 2023

These Stocks Moved the Most Today: First Republic, JPMorgan, Iveric Bio, SoFi, Norwegian Cruise, ON Semi, and More

JPMorgan Chase is acquiring all the deposits and 'substantially all of the assets' of regional lender First Republic Bank. Iveric Bio is being bought by Japan's Astellas Pharma for $5.9 billion.

Yahoo | May 1, 2023

Read More 'ISEE' Stories Here

ISEE Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 38.43%
3-year 591.18%
5-year 2,733.33%
YTD N/A
2023 0.00%
2022 28.05%
2021 141.97%
2020 -19.46%
2019 615.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!